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Abstract This study aimed to understand whether and how highly active antiretroviral treatment
(HAART) affects views and patterns of disclosure and how disclosure interacts with treatment
decisions. One hundred and fifty-two HIV-positive adults (52 MSM, 56 women and 44 IDU men)
from four US cities participated in two to three-hour, semi-structured interviews in 1998/99. Results
indicate that HAART interacts with and shapes HIV disclosure issues in several ways. Medications
may ‘out’ people living with HIV. Thus, in different settings (e.g. work, prisons, drug rehabs and
public situations), some try to hide medications or modify dosing schedules, which can contribute to
non-adherence, and affect sexual behaviours. Disclosure of HIV and/or HAART may also result in
antagonism from others who hold negative attitudes and beliefs about HAART, potentially impeding
adherence. Observable side effects of medications can also ‘out’ individuals. Conversely, medications
may improve appearance, delaying or impeding disclosure. Some wait until they are on HAARTand
look ‘well’ before disclosing; some who look healthy as a result of medication deny being HIV-positive.
Alternatively, HIV disclosure can lead to support that facilitates initiation of, and adherence to,
treatment. HIV disclosure and adherence can shape one another in critical ways. Yet these interactions
have been under-studied and need to be further examined. Interventions and studies concerning each
of these domains have generally been separate, but need to be integrated, and the importance of
relationships between these two areas needs to be recognized.
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Introduction
Disclosure of HIV serostatus continues to pose fundamental problems for people living with
HIV (PLWH), but have shifted due to the advent of new medications, in ways that have not
been fully explored. Researchers have highlighted numerous issues associated with HIV
disclosure to partners, family, colleagues and health care providers (Klitzman & Bayer, 2003;
Sepkowitz, 2001), yet the relationships between decisions about disclosing and about starting
and adhering to highly active antiretroviral treatment (HAART) have been under-studied.
Does disclosure always facilitate adherence? Does adherence facilitate disclosure? Many
advocates have hoped that improved treatment would lessen the stigma associated with HIV
and ease the lives of PLWH. But do individuals who are or are not ‘out’ about their HIV status
confront different issues when taking medications?
Issues of HIV disclosure and adherence to HAART have been examined separately
within the literature. The decision to disclose is complex and may potentially involve
significant anxiety, stigma and shame, leading to isolation or even threats to personal safety
(Klitzman, 1999; Klitzman & Bayer, 2003; Stein et al ., 1998). Consequently, a significant
number of PLWH do not disclose to sexual partners (Perry et al ., 1990; Stempel et al ., 1995).
The relationship between HIV disclosure and sexual risk behaviour is complex.
Disclosure may be associated with reduced sexual risk behaviour (Kalichman & Nachimson,
1999) and having fewer sexual partners (Marks et al ., 1991). Perceived partner serostatus may
influence these patterns. Unprotected sex may be more likely in seroconcordant couples who
have disclosed (Marks et al ., 1994). In another study, 40% of PLWH did not inform all sexual
partners of their status, but were more likely than disclosers to use condoms regularly (Marks
& Crepaz, 2001). Individuals may feel that safer sex obviates the need for disclosure.
Many infected individuals do not inform parents and siblings due to complex personal,
health and family concerns, including the emotional needs of children, family finances and
associated stressors (DeMatteo et al ., 2002). Approximately 90% of women revealed their
HIV status to their lovers, although only half or less did so with family (Simoni et al ., 1995).
In another study, 57% disclosed to their children (Kirshenbaum, 1999; Kirshenbaum &
Nevid, 2002). In general, disclosure occurs due to a sense of moral responsibility, needs for
support or, with partners, concerns for the latter’s health. Non-disclosure results from fears of
rejection, feelings of dependence or shame, and desires to maintain secrecy and/or protect
others from emotional distress (Klitzman & Bayer, 2003; Simoni et al ., 1995). Disclosure may
have a variety of negative consequences such as rejection or even violence (Gielen et al .,
2000a,b).
Individuals may disclose to family and friends when becoming ill and no longer being
able to keep their health status a secret (Babcock, 1998; Kalichman, 1995; Mansergh et al .,
1995). But disease progression is not necessarily related to disclosure to sexual partners
(Mansergh et al ., 1995; Perry et al ., 1994; Serovich, 2001). With the increased availability and
effectiveness of HAART, the relationship between disease progression and disclosure may be
less clear. PLWH may selectively disclose if the anticipated rewards outweigh the perceived
costs (Derlega et al ., 1993), but it remains unclear how individuals determine such costs and
rewards, and vary in such assessments (Klitzman & Bayer, 2003).
Adherence to HAART is medically important for treatment success (Chesney et al .,
2000; Crespo-Fierro, 1997; Kastrissios et al ., 1998; Molaghan, 1997; Paterson et al ., 2000;
Rodriguez Rosado et al ., 1998) to avoid viral resistance (Paterson et al ., 2000; Wahl & Nowak,
2000) and to increase survival (Garcia de Olalla et al ., 2002). Improved and simpler dosing
schedules do not alleviate the need for regular dosing or concerns about viral resistance.
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Overall, four groups of factors have been associated with adherence: (1) patient factors;
(2) medication characteristics; (3) interpersonal characteristics (e.g. social supports); and (4)
the general health care system (Chesney et al ., 2000; Remien, 1998). Yet a deficit of scientific
information exists on how disclosure issues relate to these domains. Disclosure may help or
hinder social support.
Although research on HIV disclosure after the advent of HAART is abundant, few, if any
studies , have examined disclosure as it directly relates to HAART-associated issues . While some
studies of disclosure include CD4 count and other medical indicators as variables of interest,
the role of HAART and adherence have received little attention in the disclosure literature. In
one of the only studies, Mellins et al . (2002) found disclosure of maternal HIV status to
children to be related not to adherence to HAART, but to ability to adhere to medical
appointments. As a reason for missing doses, not wanting others to see one taking medication
is often reported (Chesney et al ., 2000; Gifford et al ., 2000). Similarly, HIV-associated stigma
can impede treatment seeking and medication acceptance and adherence (Chesney & Smith,
1999). Side effects can reduce quality of life (Johnson et al ., 2003b) and are associated with
non-adherence (Ammassari et al ., 2001; Johnson et al ., 2002; Remien et al ., 2003; Johnson et
al ., 2003a). For example, lipodystrophy may be associated with both feelings of being
recognizable as HIV-positive (Oette et al ., 2002) and failure to adhere to HAART (Duran et
al ., 2001).
Thus, critical questions remain. Does HAART affect views and patterns of disclosure




We conducted in-depth interviews with HIV-positive men and women in Los Angeles,
Milwaukee, New York and San Francisco between 1998 and 1999 as the initial formative
phase of an intervention trial which entered the field in the spring of 2000, and was designed
to improve coping skills, reduce transmission risk behaviours and improve medical adherence
and other health care behaviours. Interviews covered a wide range of areas enabling us to
increase our understanding of issues faced by HIV-positive individuals post-HAART.
Interview data were used to inform the tailoring of the intervention to our study sub-
populations, and train staff regarding the issues most relevant to participants.
Participants and eligibility
A total of 152 in-depth interviews were conducted with HIV-positive adults, including 52 men
who have sex with men, 56 women and 44 male injection drug users. Individuals were eligible
to participate if they were HIV-positive, at least 18 years old, able to complete the interview in
English and able to give informed consent. Sixty interviews (20/sub-group) were conducted in
New York (the lead site in this phase of the trial) and approximately 30 interviews (ten/
subgroup) in each of the other sites.
Procedures
Participants were recruited from HIV primary care clinics and community-based organiza-
tions via provider referrals, word-of-mouth or study announcements at recruitment sites or in
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newsletters. Those interested contacted study staff, via telephone or in person, on site. Staff
described study objectives and procedures to potential participants and obtained consent for
enrollees. Experienced interviewers with master’s level social science education received
centralized comprehensive training with ongoing supervision. Interviews lasting two to three
hours followed a structured schedule of open-ended questions with follow-up probes as
needed. Participants provided informed consent, and were paid $25 for completing the
interview. All interviews were audiotaped and transcribed.
Assessment interview
Interviews were broad based and designed to elicit the meanings, norms, interpersonal
contexts, daily routines and other defining features of participants’ lives in their own terms
and words (Patton, 1990; Strauss & Corbin, 1990) that could be expected significantly to
affect health, sexual and drug use behaviours, psychological and practical adaptation to HIV,
and preferences for and participation in a behavioural intervention. Integral to these
interviews were sections on HIV disclosure and HAART. All participants were asked the
following: How do you think the people in your life think about you taking/starting/stopping
the medications? What gets in the way of taking the medication? What helps you be able to
take the medication the way the doctor prescribed? Did you tell your physician that you
stopped taking the medication? Do you tell your sexual partners that you have HIV or do you
keep it to yourself? Why/Why not? Participants were asked how the following targets have
reacted to their having HIV: family; doctors, nurses and other health care providers (outside
of HIV clinics or agencies) friends; people in the neighbourhood; landlords, coworkers and
employers. Interviewers were instructed to probe independently as necessary, to ascertain
more fully the respondent’s awareness, knowledge, attitudes and actual experiences
concerning these issues.
Analysis of qualitative data
Analyses were informed by grounded theory (Strauss & Corbin, 1990) and were conducted in
two phases. In the first phase, investigators reviewed transcripts to identify primary coding
categories across the broad range of topics covered, as well as a range of sub-codes and themes
present within each topic area. Identified coding categories and themes were organized into a
formal codebook. A coding team of eight evaluated four transcripts (one from each city, across
sub-populations) as a group to establish coding consensus and refine coding schema. New
themes that did not fit into this original coding framework were discussed, and modifications
were made when deemed appropriate. We refined, merged or sub-divided thematic categories,
when suggested by associations, overlap or diversions in the data. Inter-rater discrepancies
were discussed until obtaining a consensus. This process was repeated until all raters achieved
concordance on almost all decisions, after which pairs of evaluators from the larger team
coded additional interviews (n/38) until reaching a clear saturation for major and minor
themes and codes.
Based on our analyses of this data set as a whole, several themes emerged concerning the
complex relationships between disclosure and HAART. Hence, the second phase of analyses
examined data from all 152 interviews and focused on the variables we found to be most
salient and relevant to these relationships. At the same time, we explored these issues within
the broader context of participants’ lives. We organized and identified themes into formal
coding grids and extracted illustrative quotes relevant to these themes from the original
transcripts. At least two members of the data analytic team conducted analyses to ensure
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coding reliability. Findings report on the patterns of relationships between variables found to
be most significant. Our analyses did not indicate the clear presence of other variables that
would significantly alter an understanding of the pattern of relationships described here. The
themes found and described here also appeared to have face validity.
Results
Sample description
Table 1 presents demographic and background data for the sample (N/152). The majority of
individuals in each sub-group ranged in age from late thirties to early forties, and currently
took HIV medication therapy.
Several key themes emerged in the data, including relationships between disclosure and
HAART (see Figure 1).
Taking HAART as precipitating HIV disclosure
Taking medications may ‘out’ infected individuals. Such concerns arise in different settings*/
particularly at work and in other public environments. Even within the confines of one’s own
home, one’s status could be inadvertently disclosed to others. As one gay man said, ‘Some
friends came over to my house and opened the medicine cabinet. They got a shock, ‘‘Oh my
God, what is all this?’’’ (NY MSM). As a result, many try to hide medications, and/or adopt
dosing schedules and routines to conceal their pill taking as well as their diagnosis from
others, which can cause additional stress:
Sometimes I may be out somewhere and I have to take my pills. So I would want to sneak
off into this quiet little corner and take my pills or go in the bathroom. You want to be
sure you don’t leave them in your medicine chest at home. You’re always feeling like
you’re trying to cover up something, and that could be an emotional hassle, a mental
strain on yourself, too (LA MSM).
Some attempt to disguise the nature of their medication:
I usually hide it. I rip all the insignias off the bottle so if anybody did see the bottle, they
wouldn’t know even what the pills are. Because I don’t want anybody to know (LA
MSM).
Others were more comfortable taking medication at work or in public, but reported lying
about their reasons for having to take pills:
Especially when I was working, I had to stop when I had to take some medication. People
are like, ‘What are you taking?’ You just come up with some off-the-wall excuse. . ..Just,
oh, you know, it’s the only thing that keeps my nerves, just like, level here, you know,
because this is just stressful right now. It’s kind of hard to hide yourself and take your
medication (LA MSM).
In institutionalized settings such as prisons or drug treatment centres, individuals had
diminished ability to maintain privacy around issues of medication, and many felt compelled
to lie about or disguise their medication. Inadvertent disclosure of HIV status could result
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from structural and organizational factors, such as being assigned to an HIV/AIDS ward or
having to wait in queues for medication. One woman said about her detox:
I don’t like standing in no line, with everybody looking at me taking that many pills a day.
But I was in detox one day and a girl seen me get all these. . . ‘Good Lord, why you taking
so much medicine?’ I didn’t know what to say. I said, ‘I don’t know what all this shit is.
Some vitamins.’ I lied. Some people I don’t tell (NY WOM).
Medications and treatment necessitate medical visits that can also ‘out’ one or be a source of
shame:
Everything is very secretive. I can’t talk about this with anybody. No one knows I have it,
so therefore, my medications. . .if I’m going to the doctor’s, I go by myself and nobody
knows I’m there. Nobody knows I’m here. It took me several months to even come to this
Table 1. Demographic and background variables of sample (N/152)a
Variable %Women (n/56) %MSM (n/52) %IDU (n/44)
Years of age (mean, SD): 39.4 (8.7) 40.0 (6.5) 42.8 (6.8)
Range (min/max) 20/55 28/56 32/59
Ethnicityb
White, non-Latino 15.1 50.0 30.2
Latino 20.8 16.6 44.2
African or Caribbean American 60.4 31.0 23.3
Other 3.7 2.4 2.3
Educationc
Never completed high school or GED 40.4 8.8 19.0
High school or GED 34.6 37.8 40.5
Some college 23.1 22.2 33.3
College or post-college 1.9 31.2 7.2
Primary income source
Own job 16.4 22.9 0.0
Disability 54.5 56.3 57.2
Public assistance, non-disability 21.8 12.5 23.8
Family/friend/partner/spouse support 3.6 0.0 0.0
Other 3.7 8.3 19.0
Current marital status
Single 39.2 82.4 53.5
Married or common-law 30.4 4.0 16.3
Divorced, separated, or widowed 30.4 13.6 30.2
Current relationship status
Not in a relationship 16.1 60.0 52.3
In a relationship but not living together 35.7 22.0 22.7
In a relationship and living together 48.2 18.0 25.0
Substance use
Lifetime IDU 47.2 26.0 100.0
HIV medication therapy
Current 75.0 66.7 72.7
Past 12.5 21.6 15.9
Never been on meds 12.5 11.7 11.4
a Percentage of those with valid data; missing data did not exceed 8% for any variable unless specified; b missing
data for MSM on ethnicity/19.2% (n/10); c missing data for MSM on education/13.5% (n/7).
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building. I couldn’t do it. I would literally go around the back and sneak in or wait until
no cars are coming. I wear dark shades. I come in the back way. I’m just devastated,
scared. If somebody’s dropping me up here, I’ll have them drop me several blocks away
because I don’t want the association. It’s just something I’m ashamed of. I can’t help it
but it’s a reality (LA MSM).
Side effects of HAART as precipitating disclosure
Adverse side effects can also serve as non-verbal signs of illness and thus can ‘out’ individuals.
Some are acutely aware of negative physical changes due to medications:
It has aged me terribly. I look at least ten years older than I normally would. The AZT
greyed my hair, wrinkled my face, and that damage never. . .never went back. It just did it
permanently. I find this particular mix is not harmful to my face or my body outside of
the bloating which I went through for five years. I no longer bloat at all. I can get into
clothes I had when I worked at the store, and I’m so delighted I got a wardrobe. But it
makes a difference because. . .it’s hard to feel good about oneself. I don’t care what the
facade is. . .it’s very difficult to feel you look good and feel good (SF IDU-MSn).
Some avoided taking medications at work because of shorter-term side effects that others
might observe: ‘[At work, medications] start to nauseate me and make me feel drawn and
tired and sluggish’ (LA MSM).
FIG. 1. Interrelationships between disclosure and HAART.
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Therapeutic effects of HAART as delaying or impeding disclosure
The desired therapeutic effects of HAART can delay or impede disclosure. Several expressed
their desire to avoid the stigmatizing signs of advanced HIV disease and instead to appear
healthy. This desired healthy appearance enabled individuals to ‘pass’ (Goffman, 1961) as
healthy, creating additional disclosure options. For example, some delay disclosure, waiting
until they are on medications and looking ‘well’:
I did not tell them until I was on the meds and [the meds] were working, because I didn’t
want them to worry, ‘Oh, he’s going to die. He’s going to die.’ I just wanted them to know
that I’m part of the cure and not the problem’ (LA IDU).
Conversely, as a result of HAART and looking healthy, some are able to deny that they are
HIV infected:
They don’t know. They started a rumour, but I don’t look it. Do you know what an HIV
guy looks like? He don’t look like me. I’m built. I’m big. They’re skinny. They can barely
walk. I just convince them quick (LA IDU).
Closetedness about medication as promoting non-adherence
A perceived need not to disclose can foster non-adherence. As one IDU reported:
I have to remember to take them. At first I felt conscious about taking them out when it
was time to take them. Or having them with me. Or people would ask me, ‘what are you
taking?’ And I would miss dosages like that (NY IDU).
One gay man missed doses of medications because he was afraid medications would ‘out’
him to sexual partners to whom he had not disclosed his HIV status:
I am very careful about spending the night over at somebody’s house. I’ll be very careful
of letting them see me take my medication because they might be curious about, ‘What
kind of medication you taking?’ Then you have to [explain] it (MIL MSM).
Disclosure impeding adherence
As a result of openness about being HIV infected and on medications, some faced
antagonistic reactions from others who hold negative beliefs or expectations of HAART
(e.g. because of adverse side effects) that can then impede adherence:
Other patients that come over here, or I see, say, ‘Oh, you shouldn’t take those pills.’ Or,
‘Those pills are no good because they make your stomach look big,’ and stuff like that
(NY WOM).
Following disclosure, antagonism toward medications may also arise due to mistrust about the
medical establishment in general:
I heard so many different diverse opinions about it from different people*/‘Those things
are gonna kill you, that shit don’t work, they’re using you as a guinea pig,’ that together
with the way that I was taking them too erratically, it worked on me (NY IDU).
HIV DISCLOSURE AND HAART 635
Such opposition can also arise after disclosure due to political views and distrust based on
historical instances of discrimination and medical experimentation:
Initially, my ex wasn’t crazy about it. He’s African-American. . .and you know the first
thing he thought was the Tuskegee experiments. He had it in his head that somebody
deliberately gave me this because I’m Native American and have half-black children. He
was way into all that conspiratorial evil stuff (LA WOM).
Some are able to counter such antagonism effectively*/recognizing its basis in
misinformation, or their own right to autonomous decision making. Yet responding effectively
to such antagonism may not be easy:
Because of all the misinformation out there, a lot of people are ignorant about protease
inhibitors, and I had to get that straight in my mind and with my health care provider. I’m
pretty well informed about it now (NY IDU).
One woman said her boyfriend is ‘anti-medication’: ‘That’s his individual choice, but he
doesn’t tell me not to take it. I would tell him to go take a hike anyway’ (NY WOM).
Disclosure facilitating adherence
On the other hand, in the era of HAART, HIV disclosure can also lead to social support that
can promote health and facilitate starting and adhering to treatment:
If I would have told them when I first found out, then maybe I could have got help back
then, and my disease wouldn’t have progressed as rapidly as it did. So I think it’s more
out of self-pity and demoralization that I didn’t tell them earlier (LA IDU).
Many participants reported that individuals within their social network to whom they had
disclosed reacted positively, and often asked if these participants were keeping up with their
medication regimens*/showing support, involvement and acceptance: ‘Just my boyfriend
knows. . .. He gets on me: makes sure I take it every day’ (MIL WOM).
Indeed, infected individuals often appreciate this support:
They’re always on my back to make sure I take my medications. . .my wife, my mother,
my brother, people that care, that support me. They’re always aware. At the time I’m
supposed to take the medication, they’ll call me. . .I just like the support. I appreciate that
very much (NY IDU).
Yet positive social support, although facilitating adherence, may also create certain burdens or
pressures due to overly optimistic expectations concerning these treatments:
My mother thinks, ‘oh, you’re taking medication, you’re going to live a long time.’ But
when the virus hits you, there’s nothing you can do. She figured, ‘oh you take the
medication, you’re going to be all right.’ I explained to her what I know about it: that
that’s not so (NY WOM).
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Discussion
HIV disclosure and adherence to HAART can shape each other in several important ways. On
the one hand, HAART can ‘out’ individuals, leading to efforts to disguise medications or alter
treatment regimens, in turn potentially affecting adherence. The physiological effects of these
medications*/both good and bad*/can also shape disclosure. Side effects can serve as a
proxy for disclosure, and beneficial effects can make it easier to delay or avoid divulging one’s
status. Disclosure can also facilitate initiation and maintenance of treatment. Yet at times, the
interplay between disclosure and adherence reveals a conflict of goals. The desire to stay
healthy and fight HIV (by taking medications) may conflict with a desire to maintain privacy
about one’s HIV status (by not taking the medications around other people). Disclosure may
also be a key variable in obtaining or mediating social support, which can be important in
adherence.
These dynamics between disclosure and adherence have been under-studied and need to
be further examined. Attention has generally been given, on the one hand, to interventions
and approaches for assisting individuals with issues of disclosure; and on the other hand,
toward enhancing medication adherence. The interconnections*/both positive and
negative*/between these two sets of issues in the lives of PLWH need to be more fully
appreciated and explored. At the same time, the potential impact of disclosure on adherence
calls for renewed and revised attention to issues of disclosure in HIV prevention efforts and
research. The disclosure literature has focused little, if at all, on issues of adherence. Further
research on disclosure should examine the ways in which these decisions interact with
adherence patterns*/how fears of disclosure may impede or enhance adherence, and how
HAART may delay disclosure in ways that can in turn facilitate the practice of unsafe sex that
further transmits the virus. Such delays in disclosure may also lead to an individual receiving
less support than he or she otherwise might, in ways that may diminish adherence. Thus, a
better understanding of the dynamics between desires to adhere to medications on the one
hand, and to maintain privacy on the other, can inform the development of interventions that
allow for rational non-disclosure that does not result in decreased adherence. Despite
treatment regimens becoming easier than in the past (e.g. with fewer pills) and stress related
to the need to take pills in public decreasing to some extent, these issues remain a significant
problem for many PLWH.
In conclusion, future studies in each of these two domains*/disclosure and adherence*/
would benefit from greater recognition of the significance of these complex interactions. In
this way, researchers, clinicians and others can advance appropriately nuanced understanding
and sensitivity regarding these issues, improve the health and quality of life of infected
individuals and stymie the continued spread of the epidemic.
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